Biotech Values

[DewDiligence]

2Q09 Worldwide and US Drug-Eluting Stent Sales

[Sales of Promus, Taxus, Cypher, and the total market are as
reported by BSX, BSX, JNJ, and BSX, respectively; sales of Xience
and Endeavor are my estimates derived from divisional sales
figures provided by ABT and MDT, respectively, and approximate
market-share figures furnished by BSX. (Note: MDT’s fiscal calendar
is out of phase with the other three companies.) All sales in $million.]

 
                -Worldwide-   ----US-----   ---Ex-US--- 
                Sales Share   Sales Share   Sales Share 
 Xience           263  25%      128  27%      135 24% 
 Promus           172  16%      127  26%       45  8% 
 ======         ===== =====   ===== =====   ===== ===== 
 Xience/Promus    435  41%      255  53%      180 32% 
 Taxus            269  26%      111  23%      158 28% 
 Cypher           235  22%       70  14%      165 29% 
 Endeavor         110  10%       48  10%       62 11% 
 ========       ===== =====   ===== =====   ===== ===== 
 TOTAL          1,049 100%      484 100%      565 100%